Veracyte alternatives and competitors

Valar Labs is a precision oncology company, founded in 2021, whose tests predict treatment response and prognosis from routine H and E slides using its Computational Histology AI platform, trained on more than 500,000 pathologist annotations.

Price: Per test, ordered from the vendor's own laboratory

ArteraAI is the Los Altos, California company at artera.ai that builds multimodal AI cancer tests. It is unrelated to Artera of Santa Barbara (artera.io), which makes patient communication agents.

Price: No list price published; patient cost $0 to $285 under the financial assistance program, and none for covered Medicare patients

Caris Life Sciences (NASDAQ: CAI) is a precision oncology company in Irving, Texas. It profiles tumors in its own laboratories by whole exome and whole transcriptome sequencing and layers AI signatures on the results.

Price: No published price

bioAffinity Technologies (NASDAQ: BIAF) develops noninvasive tests for lung disease, led by CyPath Lung, a laboratory developed test that pulmonologists and other physicians order for high risk patients with indeterminate pulmonary nodules.

Price: No published price

Multi cancer early detection company (NASDAQ: GRAL). The Galleri test uses targeted methylation sequencing of cell free DNA from a blood draw, with machine learning classifiers that detect a cancer signal and predict its origin, across more than 50 cancer types.

Price: $949 per test (list price)

PreciseDx sells PreciseBreast, a test that predicts whether early breast cancer will come back, using AI to read the cell patterns on a routine stained slide.

Price: No published price

Stratipath Breast assigns early stage invasive breast cancers to low or high risk groups from routine H&E slides, as a faster, cheaper alternative to gene expression tests for pathology laboratories and breast cancer teams in Europe.

Price: No published price

Precision oncology company in Waltham, Massachusetts, combining sequencing in its own CAP accredited, CLIA certified laboratory with models of tumor and immune biology.

Price: No published price

Cancer screening company (NASDAQ: FRNM) whose blood tests run on a multiomics platform that reads cell free DNA methylation at single base resolution, alongside protein and autoantibody signals, with machine learning classifiers producing the result.

Price: No published price

Rare disease genomic diagnosis company (NASDAQ: WGS) in Gaithersburg, Maryland, running exome and genome sequencing in its own accredited laboratory and interpreting it with automation, machine learning and clinical scientists over GeneDx Infinity, its dataset of prior cases.

Price: No published price